COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency
Preliminary findings show VenoValve as cost-effective & clinically beneficial for severe CVI. Webcast discussing results. Potential $5.9B annual healthcare savings. Study shows cost savings and clinical benefits -
-
-
COMMUNIQUÉ DE PRESSE
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
enVVeno Medical is developing the VenoValve as a potential treatment for Chronic Venous Insufficiency. FDA decision expected in 2H'2025 -
-
-
